Efficacy of prompt administration of cryoprecipitate in severe postpartum hemorrhage of preeclampsia patients.
coagulation factors
cryoprecipitate
fibrinogen
hypertension
postpartum hemorrhage
preeclampsia
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
30
06
2023
accepted:
01
09
2023
medline:
5
12
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
ppublish
Résumé
Cryoprecipitate (CRYO) is a concentrated preparation of coagulation factors formulated from fresh frozen plasma (FFP), which can replenish coagulation factors rapidly. Preeclampsia (PE) is frequently associated with postpartum hemorrhage (PPH), and the rapid replenishment of coagulation factors is vital in the management. We conducted a retrospective cohort study to determine the efficacy of administering CRYO irrespective of fibrinogen levels in patients with PE who experienced severe PPH. Patients with PPH accompanied by PE and those who required red blood cell (RBC) transfusion were included. Cases were divided into two groups: those treated with CRYO (N = 16) and those not treated with CRYO (N = 10). The total transfusion volume, blood loss before and after transfusion initiation, duration of hospitalization, presence of pulmonary edema, and performance of either interventional radiology or hysterectomy were compared. The median fibrinogen levels before transfusion were 2.24 and 2.34 g/L in the CRYO group and the not using group, respectively. Although blood loss before transfusion was comparable between the two groups, blood loss after transfusion was significantly less in the CRYO group (median: 520 vs. 2352 mL, p = 0.015), as well as the total blood loss (median: 2285 vs. 3825 mL, p = 0.005) and total transfusion volume (median: RBC 6 vs. 16 U, p = 0.01, FFP 10 vs. 20 U, p = 0.017). Prompt replenishment of coagulation factors using CRYO to patients with PE who experience severe PPH could decrease further bleeding.
Substances chimiques
Blood Coagulation Factors
0
Hematologic Agents
0
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2811-2816Informations de copyright
© 2023 Japan Society of Obstetrics and Gynecology.
Références
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.
Sato K, Seki H, Sakamoto H. Role of prostagalandins in pregnancy-induced hypertension. Am J Kidney Dis. 1991;17:133-138.
Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol. 1985;152:335-340.
Clark BA, Halvorson L, Sachs B. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol. 1992;166:962-968.
Hypertension in pregnancy report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122-1131.
Haram K, Mortensen JH, Mastrolia SA, Erez O. Disseminated intravascular coagulation in the HELLP syndrome: how much do we really know? J Matern Fetal Neonatal Med. 2017;30:779-788.
Offer E, Maha O, Anat R, et al. DIC in pregnancy - pathophysiology, clinical characteristics, diagnostic scores, and treatments. J Blood Med. 2022;13:21-44.
von Schmidt JF, Hukkelhoven CWPM, Van Roosmalen J, et al. Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in The Netherlands. PLoS One. 2013;8(12):e81959. https://doi.org/10.1371/journal.pone.0081959
McLintock C, James AH. Obstetric hemorrhage. J Thromb Haemost. 2011;9:1441-1451.
Makino S, Takeda S, Kobayashi T, Murakami M, Kubo T, Hata T, et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: investigated by the perinatology committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015;41:1155-1160.
Kamidani R, Miyake T, Okada H, Yoshimura G, Kusuzawa K, Miura T, et al. Effect of cryoprecipitate transfusion therapy in patients with postpartum hemorrhage: a retrospective cohort study. Sci Rep. 2021;11(1):18458.
Prevention and Management of Postpartum Haemorrhage: Green-top guideline No. 52. BJOG. 2017;124:e106-e149.
Wilkkelso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth. 2015;114(4):623-633.
Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage-an observational study. Transfus Med. 2012;22:344-349.
Gollop ND, Chilcott J, Benton A, Rayment R, Jones J, Collins PW. National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfus Med. 2012;22:350-355.
Kikuchi M, Itakura A, Miki A, Nishibayashi M, Ikebuchi K, Ishihara O. Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res. 2013;39:770-776.
James AH, McLintock C, Lockhart E. Postpartum hemorrhage: when uterotonics and sutures fail. Am J Hematol. 2012;87(Suppl 1):S16-S22.
Escobar MF, Nassar AH, Theron G, Barnea ER, Nicholson W, Ramasauskaite D, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynecol Obstet. 2022;157(Suppl. 1):3-50.
Sentilhes L, Vayssiere C, Mercier FJ, et al. Postpartum hemorrhage: guidelines for clinical practice-text of the guidelines. J Gynecol Obstet Biol Reprod. 2014;43:1170-1179.
Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. Am J Obstet Gynecol. 2016;215:B17-B22.
Green L, Daru J, Gonzalez Carreras J, et al. Early cryoprecipitate transfusion versus standard care in severe postpartum haemorrhage: a pilot cluster-randomised trial. Anaesthesia. 2022;77:175-184.
Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth. 2012;108:984-989.
Shoko O, Tetsuya H, Mitsuru W, et al. Fibrinogen measurement by a novel point-of-care device with whole blood: comparison of values against Clauss method. J Anesth. 2021;35(5):757-760.
Coopland A, Alkjaersig N, Fletcher AP. Reduction in plasma factor 13 concentration during pregnancy. J Lab Clin Med. 1969;73:144-153.
Haslinger C, Korte W, Hothorn T, Brun R, Greenberg C, Zimmermann R. The impact of prepartum factor XIII activity on postpartum blood loss. J Thromb Haemost. 2020;18:1310-1319.
Callum J, Farkouh E, Scales C, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322:1966-1976.